Ryan Deschner
Stock Analyst at Raymond James
(4.79)
# 97
Out of 4,966 analysts
17
Total ratings
93.75%
Success rate
41.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ryan Deschner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LQDA Liquidia | Maintains: Strong Buy | $33 → $41 | $27.68 | +48.12% | 4 | Aug 13, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Strong Buy | $29 → $27 | $7.26 | +272.16% | 3 | Aug 8, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Outperform | $54 | $53.88 | +0.22% | 1 | Aug 6, 2025 | |
| ARDX Ardelyx | Maintains: Outperform | $11 → $12 | $6.36 | +88.68% | 2 | Aug 5, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $52 → $50 | $27.57 | +81.36% | 2 | Aug 1, 2025 | |
| VKTX Viking Therapeutics | Maintains: Strong Buy | $125 → $122 | $27.05 | +351.02% | 1 | Jul 24, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Outperform | $62 | $29.92 | +107.22% | 1 | Jul 14, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Strong Buy | $26 → $28 | $11.62 | +140.96% | 3 | Jan 14, 2025 |
Liquidia
Aug 13, 2025
Maintains: Strong Buy
Price Target: $33 → $41
Current: $27.68
Upside: +48.12%
Trevi Therapeutics
Aug 8, 2025
Maintains: Strong Buy
Price Target: $29 → $27
Current: $7.26
Upside: +272.16%
Palvella Therapeutics
Aug 6, 2025
Initiates: Outperform
Price Target: $54
Current: $53.88
Upside: +0.22%
Ardelyx
Aug 5, 2025
Maintains: Outperform
Price Target: $11 → $12
Current: $6.36
Upside: +88.68%
Apellis Pharmaceuticals
Aug 1, 2025
Maintains: Outperform
Price Target: $52 → $50
Current: $27.57
Upside: +81.36%
Viking Therapeutics
Jul 24, 2025
Maintains: Strong Buy
Price Target: $125 → $122
Current: $27.05
Upside: +351.02%
Tvardi Therapeutics
Jul 14, 2025
Initiates: Outperform
Price Target: $62
Current: $29.92
Upside: +107.22%
ARS Pharmaceuticals
Jan 14, 2025
Maintains: Strong Buy
Price Target: $26 → $28
Current: $11.62
Upside: +140.96%